Close Menu

SAN FRANCISCO (GenomeWeb) – Illumina today announced the launch of three new sequencing systems and provided an update on its diagnostic plans in the noninvasive prenatal testing and oncology markets.

Speaking at the JP Morgan Healthcare Conference, CEO Jay Flatley preannounced fourth quarter revenues of $512 million, as well as $1.86 billion in FY 2014 revenues, representing 31 percent year-over-year growth. He said the firm expects revenue growth of 20 percent in FY 2015.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nearly 30,000 COVID-19 tests the UK sent to the US came back as void, according to the Telegraph.

Black principal investigators receive less favorable application scores when seeking US National Institutes of Health grants, the Chronicle of Higher Education reports.

New Scientist reports that both RNA and DNA may have been involved in the emergence of life on Earth.

In Nature this week: new Sperm-seq method enables crossover analysis, tumor-informed detection approach for minimal residual disease, and more.